Evaluation of real-world cost savings and utilization of biosimilar drugs in a community-based oncology practice. This is an ASCO Meeting Abstract from the 2021 ASCO Quality Care Symposium. This ...

Targeting B-Cell Lymphoma 2: A Lethal Shortcut in Del(17p) Chronic Lymphocytic Leukemia ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...

Higher Doses of Lenalidomide Are Associated With Unacceptable Toxicity Including Life-Threatening Tumor Flare in Patients With Chronic Lymphocytic Leukemia Salvage treatment consisted of two cycles of ...

Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European ...

This prospective, multicenter, multinational study was conducted in 14 medical practices on cancer patients undergoing either HEC or MEC treatment. Patients recorded episodes of nausea and vomiting in ...

The risk of second primary malignancy in patients with localized thymoma: A U.S. population-based study. This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting I. This abstract does not ...

Members of a kindred in which six relatives in four consecutive generations comprised an autosomal dominant pattern of documented GISTs and cutaneous lesions underwent physical examination, imaging ...

From October 2000 to April 2002, 547 patients from 51 institutions were entered onto the trial. The average age was 59 years. Patients were predominately male (79%) and most continued to use tobacco ...

Breast cancer–specific PA print materials and pedometers may be effective strategies for increasing PA and QoL in breast cancer survivors. A combined approach appears to be optimal.

A randomized, placebo-controlled study of amatuximab in combination with pemetrexed and cisplatin (P/C) as front-line therapy for subjects with malignant pleural mesothelioma (MPM). Background: ...

Key issues in the development and approval of new anti-cancer immune therapies. This is an ASCO Meeting Abstract from the 2020 ASCO Annual Meeting I. This abstract does not include a full text ...